DCVMN Annual General Meeting 2026

SPI Pharma will join vaccine manufacturers and global health leaders in Beijing for the 2026 DCVMN Annual General Meeting.

The DCVMN AGM brings together members of the Developing Countries Vaccine Manufacturers' Network alongside global health organizations, donors and regulators working to improve vaccine access worldwide.

What sets the meeting apart is its focus on the priorities and day-to-day realities of vaccine manufacturers in developing countries. That makes the AGM an important forum for practical conversations around formulation, manufacturing, supply and access.

Advancing vaccine formulation with Valens™

At the show, SPI Pharma will promote their scalable vaccine adjuvant platforms, including Valens QS-21 and TLR4 agonist-based liposomal systems, as well as squalene- and alum-based technologies formulated in combination with a synthetic MPL analogue. SPI Pharma, QVANT and Inimmune are redefining what’s possible in vaccine development with advanced adjuvant systems that spark stronger immune responses and speed innovation to market. Together, we’re uniting world-class science with global scale to bring breakthrough vaccine technologies to patients worldwide.